SCHEMBL1824699

SCHEMBL1824699

COC(=O)CC(CNC(C)=O)Cc1ccc(OS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 4/20 0.44
ALDH1A1 P00352 3/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PPARG P37231 1/20 0.41
KDM4E B2RXH2 1/20 0.41
KDM4A O75164 1/20 0.41
ENPP2 Q13822 4/20 0.40
ENPP3 O14638 3/20 0.40
P2RX7 Q99572 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1826553 0.92 ENPP1 (0.45) ENPP1ALDH1A1LMNASMN1; SMN2PPARG
SCHEMBL1826739 0.90 KDM4E (0.41) ENPP1ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL1824898 0.87 P2RX7 (0.51) LMNAP2RX7KMT2AMAPT
SCHEMBL1822756 0.87 P2RX7 (0.47) ENPP1PPARGKDM4EKDM4AENPP2
SCHEMBL1824663 0.85 P2RX7 (0.55) LMNAP2RX7MAPT
SCHEMBL1828106 0.84 PPARG (0.41) SMN1; SMN2PPARG
SCHEMBL1828894 0.84 P2RX7 (0.46) ENPP1ALDH1A1LMNAPPARGKDM4E
SCHEMBL3572724 0.83 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2PPARGKDM4E
SCHEMBL1826399 0.83 ENPP1 (0.46) ENPP1ALDH1A1LMNASMN1; SMN2PPARG
SCHEMBL1822093 0.83 ALDH1A1 (0.45) ENPP1ALDH1A1LMNASMN1; SMN2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 ENPP1 3768/4885ALDH1A1 1099/4885LMNA 1802/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 ENPP1 2849/4885ALDH1A1 1440/4885LMNA 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.